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Background: Platelet-derived growth factor (PDGF) signalling is essential for many key cellular processes in
mesenchymal cells. As there is redundancy in signalling between the five PDGF ligand isoforms and three PDGF
receptor isoforms, and deletion of either of the receptors in vivo produces an embryonic lethal phenotype, it is not
know which ligand and receptor combinations mediate specific cellular functions. Fibroblasts are key mediators in
wound healing and tissues repair. Recent clinical trials using broad spectrum tyrosine kinase inhibitors in fibrotic
diseases have highlighted the need to further examine the specific cellular roles each of the tyrosine kinases plays
in fibrotic processes. In this study, we used PDGFR-specific neutralising antibodies to dissect out receptor-specific
signalling events in fibroblasts in vitro, to further understand key cellular processes involved in wound healing and
tissue repair.
Results: Neutralising antibodies against PDGFRs were shown to block signalling through PDGFRα and PDGFRβ
receptors, reduce human PDGF-AA and PDGF-BB-induced collagen gel remodelling in dermal fibroblasts, and
reduce migration stimulated by all PDGF ligands in human dermal and lung fibroblasts.
Conclusions: PDGFRα and PDGFRβ neutralising antibodies can be a useful tool in studying PDGFR isoform-specific
cellular events.Background
Platelet-derived growth factors (PDGFs) acting via their
tyrosine kinase receptors are major mitogens for many
cell types of mesenchymal origin, including fibroblasts
and vascular smooth muscle cells (VSMCs) [1-4]. Their
role in enhancing migratory and proliferative responses
and extracellular matrix (ECM) synthesis in these cells
makes them key regulators of critical biological and
pathological functions including tissue remodelling, scar-
ring and fibrosis. Two PDGF receptor (PDGFR) isoforms
(PDGFRα and PDGFRβ) form three different dimeric re-
ceptors – αα, ββ and αβ [5,6]. These receptors can inter-
act with five different dimeric PDGF ligands: PDGF-AA,
PDGF-BB, PDGF-CC, PDGF-DD and PDGF-AB [7-11],
with different specificities and efficacies [12] (Figure 1).* Correspondence: johanna.donovan@ucl.ac.uk
1Centre for Rheumatology and Connective Tissue Diseases and Division of
Medicine, UCL Medical School, Royal Free Campus, London, UK
Full list of author information is available at the end of the article
© 2013 Donovan et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orWhile PDGF ligands have considerable overlap in their
cellular signalling, individual ligands have also been found
to control, or are dominant in, specific cellular events.
PDGF-AA is a potent mitogen for cardiac fibroblasts and
has been shown to be critical in lung alveolar myofibroblast
development and alveogenesis [13,14]. PDGF-BB is re-
quired in the ontogeny of kidney mesangial cells and has
been shown to be essential for development of the vascula-
ture and vascular integrity [15]. PDGF-CC has been impli-
cated in all phases of wound healing while blockade of
PDGF-CC signalling inhibits pathological angiogenesis by
acting on multiple cellular and molecular targets [16].
PDGF-DD is thought to stimulate angiogenesis and depos-
ition of ECM and to be involved in hepatic and renal
fibrosis [17]. It is also thought to be involved in VSMC
phenotypic modulation and is upregulated in endothelial
cells exposed to atherosclerosis-prone flow patterns [18].
In vitro, PDGFR isoforms have been shown to be potent
activators of fibroblast proliferation, migration and sur-
vival [10]. Although stimulation of PDGFRα and PDGFRβal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Schematic diagram showing PDGFR-PDGF interactions in vitro: PDGF ligand dimers bind either PDGFRα or PDGFRβ
homodimers or the α/β heterodimer. Arrows show proven in vitro ligand-receptor interactions. Each PDGF receptor has five extracellular
immunoglobulin-like domains and two intracellular tyrosine kinase domains. PDGFR chains are shown in blue (PDGFRα) and red (PDGFRβ).
PDGF ligands are shown in green (PDGF-A), yellow (PDGF-B), orange (PDGF-C) and purple (PDGF-D).
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ies suggest distinct requirements for specific pathways to
initiate particular receptor-mediated functions. For ex-
ample, while activation of both receptors evoke mitogenic
signals, stimulation of PDGFRα inhibits chemotaxis of fi-
broblasts and smooth muscle cells; in contrast, PDGFRβ
activation potently stimulates fibroblast chemotaxis [9,19].
Recent studies have attempted to dissect PDGFR-
specific events using genetically defined mouse embry-
onic fibroblasts (MEFS) expressing PDGFRα, PDGFRβ,
both or neither [20]. These cells were generated by
transducing PDGFRβ−/− cells with retroviral expres-
sion vectors for PDGFRα, PDGFRβ or both. Microarray
gene expression array analysis provided some interest-
ing insights. No genes were differentially expressed in
the double null cells, suggesting minimal receptor-
independent signalling. Whilst there is considerable
overlap between PDGFRα and PDGFRβ signalling, this
study identified transcripts that were differentially
expressed between the cell lines. Thirty-three gene sets
(functional groups of genes) were activated by PDGFRα
only and 15 genes sets by PDGFRβ only. Interestingly,
25 genes sets were specifically activated by the hete-
rodimeric receptors, for example, PDGFRα/β-activated
components of the NFkB and interleukin (IL)-6 path-
ways, PDGFRα-activated C21-steroid hormone bio-
synthesis, and PDGFRβ activated the angiogenesis and
epidermal growth factor receptor (EGFR) signalling
pathways. The PDGFRα null cell line but not the
PDGFRβ null or wild type (WT) showed differentialexpression of guanosine diphosphate (GDP) signalling
genes [20]. Conversely, the differentially expressed gene
sets particular to the PDGFRβ null and WT cell lines
characterise ketosteroid metabolism [20]. Whilst these
types of studies provide a reasonable genetic character-
isation, they supply very little functional information,
especially given that MEFs do not necessarily reflect
the behaviour of adult fibroblasts.
Inhibition of both PDGFRs by broad-spectrum tyrosine
kinase inhibitors such as Gleevec (which also inhibits
c-Abl, c-kit and VEGFR) is used in the treatment of
gastrointestinal stromal tumours and chronic mylogenous
leukaemia [21-23]. They have been shown to reduce pro-
liferation of normal mesangial cells via reduction in
STAT3 phosphorylation [24] and of fibroblasts via reduc-
tion in PDGFRβ phosphorylation [25]. Gleevec treatment
has also been shown to reduce the synthesis of ECM pro-
teins in a model of dermal fibrosis [26]. These data suggest
that PDGFR is regarded as a key molecular target in the
development of anti-fibrotic therapies.
Taken together, these in vitro studies implicate
PDGFR signalling in fibroblast function during tissue
repair and scarring, however, questions still remain re-
garding the underlying mechanism(s) and specificity of
PDGF ligand-receptor function. In this report, we used
PDGFR-specific neutralising antibodies to block signal-
ling through either PDGFRα or PDGFRβ to dissect out
receptor-specific signalling events in vitro. We also ana-
lyse the role of the receptors on fibroblast migration
and collagen gel contraction.
Figure 3 Phosphorylation of PDGFRα and PDGFRβ in response
different doses of PDGF-AA and PDGF-CC ligands. Dermal
fibroblasts were grown in 10% FCS and serum-starved overnight.
Cells were stimulated with 0% FCS, PDGF-BB, PDGF-AA (5-200ng/ml)
and PDGF-CC (5-200ng/ml) for 15 min. Whole cell lysates were
Western blotted using antibodies against phospho-PDGFRα,
phospho-PDGFRβ and GAPDH (loading control).
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Phosphorylation of PDGFR by PDGFAA, BB, CC and DD
In order to establish the pattern of phosphorylation of
PDGFRs with the various PDGF ligands in human dermal
fibroblasts, cells were serum-starved overnight and stimu-
lated with PDGF-AA, PDGF-BB, PDGF-CC, PDGF-DD
(20 ng/ml) or 10% FCS, or maintained in 0% FCS for 15
min. Western blots of total cell protein were probed with
antibodies against phospho-PDGFRα, PDGFRα, phospho-
PDGFRβ, PDGFRβ and GAPDH as a loading control
(Figure 2a). Phosphorylation of PDGFRα was observed
when cells were stimulated with PDGF-BB, PDGF-DD
and, to a lesser extent, PDGF-AA. There was no detect-
able phosphorylation of PDGFRα when stimulated with
PDGF-CC. Phosphorylation of PDGFRβ was observed
after stimulation with PDGF-BB and PDGF-DD. A similar
phosphorylation pattern of PDGFRβ is observed in lung fi-
broblasts when stimulated with PDGF-AA, PDGF-BB and
PDGF-DD (Figure 2b). However, phosphorylation of
PDGFRα was observed when cells were stimulated with
all with PDGF ligands in lung fibroblasts.
To ascertain if skin fibroblast PDGFRs were phosphory-
lated at higher doses of PDGF-CC and PDGF-AA, cells
were stimulated with various concentrations of PDGF-AA
or PDGF-CC (0–200 ng/ml). Western blots of total cell
protein were probed with antibodies against phospho-
PDGFRα, phospho-PDGFRβ and GAPDH as a loading con-
trol (Figure 3). Phosphorylation of PDGFRα was observed
upon stimulation with PDGF-AA at doses 5–200 ng/ml.
PDGFRα was phosphorylated moderately at 50 ng/ml and
more strongly above 100 ng/ml by PDGF-CC. Phospho-
rylation of PDGFRβ was observed at a low level when
stimulated with PDGF-AA at doses 50–200 ng/ml. NoFigure 2 Phosphorylation of PDGFRα and PDGFRβ in response to PDG
in 10% FCS and serum-starved overnight or kept in 10% FCS. Cells were th
PDGF-DD or Imatinib for 15 min. Whole cell lysate were Western blotted u
PDGFRβ and GAPDH (loading control).phosphorylation of PDGFRβ was detected after treatment
with PDGF-CC.
Effect of blocking antibody on phosphorylation and
signal transduction
Human dermal fibroblasts were treated with PDGFRα or
PDGFRβ neutralising antibodies and stimulated with
PDGF-AA or PDGFR-BB ligands. Western blot analysis
shows that the expression of total PDGFRα, PDGFRβ and
ERK is similar across all treatment groups (Figure 4a).
Phosphorylation of PDGFRα is observed when cells are
stimulated with PDGF-AA or PDGF-BB alone and when
treated with neutralising antibodies against PDGFRα andF ligands. Dermal fibroblasts (a) and lung fibroblasts (b) were grown
en stimulated with either 10% FCS, 0% FCS, PDGF-AA, PDGF-BB,
sing antibodies against phospho-PDGFRα, PDGFRα, phospho-PDGFRβ,
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lated with either PDGF-AA or PDGF-BB. Phosphorylation
of PDGFRα was not observed when cells were treated with
either neutralising antibody alone or when treated with
anti-PDGFRα and stimulated with the PDGFRα-specific
ligand, PDGF-AA. Phosphorylation of PDGFRβ was ob-
served when cells were stimulated with the universal
PDGF ligand, PDGF-BB only and when treated with anti-
PDGFRα and stimulated with PDGF-BB. Both receptors
show enhanced phosphorylation in response to PDGF-BB
compared to PDGF-AA (pPDGFRα 7-fold difference be-
tween PDGF-AA and PDGF-BB stimulation, PDGFRβ
700-fold difference between PDGF-AA and PDGF-BB
stimulation) (Figure 4b-c). Phosphorylation of ERK is re-
duced in cells treated with anti-PDGFRα compared to
controls (Figure 4a), but not when treated with anti-
PDGFRβ. The PDGF receptor neutralising antibodies were
also observed to block phosphorylation of their respective
homodimer receptors in lung fibroblasts (Figure 4d-f).Figure 4 Western blot showing effects of PDGFRα and PDGFRβ neutr
neutralising antibodies to anit-PDGFRα, anti-PDGFRβ or vehicle for 1 h at ro
PDGF-BB or vehicle for 15 min. Cells were then washed in ice-cold PBS and
PDGFRβ, pPDGFRβ, ERK, pERK and GAPDH. The relative amount of pPDGFR
(d) Lung fibroblasts were treated and analysed in the same manner (e) andPhosphorylation of ERK was observed with most
treatments.
Effects of PDGFR neutralising antibodies on collagen gel
contraction
To analyse the effect of PDGFR neutralising antibodies on
the ability of fibroblasts to contract collagen gels, dermal
fibroblasts were treated with anti-PDGFR neutralising
antibodies prior to embedding in collagen gels. The gels
were then incubated in medium containing PDGF-AA,
PDGF-BB or a 0% serum (control) for 24 h. The gel diam-
eter was measured and gels weighed. Both PDGF-AA and
PDGF-BB significantly induced collagen gel contraction in
human dermal fibroblasts compared to 0% FCS (Figure 5)
(p = 0.004 and p = 0.032 respectively). A similar effect was
observed in gels where the cells were treated with anti-
PDGFRα and stimulated with PDGF-BB (p = 0.031) or
anti-PDGFRβ and stimulated with either PDGF-AA or
PDGF-BB (p = 0.035 and p = 0.0007) compared to control.alising antibodies. (a) Dermal fibroblasts were treated with
om temperature and then stimulated with either PDGF-AA or
lysed. Cell lysates were Western blotted for PDGFRα, pPDGFRα,
α, pPDGFRβ, as measure by densitometry, is shown in (b) and (c).
(f).
Figure 5 The effect of collagen gel contraction of dermal
fibroblasts after treatment with PDGFRα and PDGFRβ
neutralising antibodies. Dermal fibroblasts were treated with
neutralising antibodies to anti-PDGFRα, anti-PDGFRβ or blank for 1 h
at room temperature and were added to a collagen gel. The gels
were then grown in media containing either PDGF-AA or PDGF-BB.
After 24 h the gels were weighed to assess contraction. Error bars
are standard error of the mean. Two-sample T-test statistical analysis
was performed compared to compared gel weights compared to
the 0% FCS control p = 0.004 PDGF-AA, p = 0.032 PDGF-BB, p = 0.82
anti-PDGFR-α., p = 0.62 anti-PDGFR-α.+ PDGF-AA, p = 0.03 anti-
PDGFR-α.+ PDGF-BB, p = 0.77 anti-PDGFR-β, p = 0.035 anti-PDGFR-β +
PDGF-AA, p = 0.0007 anti-PDGFR-β + PDGF-BB. *p > 0.05.
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contraction induced by the PDGFRα-specific ligand PDGF-
AA (p = 0.62). Treatment with either antibody alone had
no effect on collagen gel contraction.
Effect of PDGFR neutralising antibodies on fibroblast
migration
To investigate the effect PDGFR-neutralising antibodies
on PDGF-mediated migration, a scratch wound assay
was performed in dermal and lung fibroblasts. Cells were
cultured in the presence of anti-proliferative agent, mito-
mycin C, treated with PDGFR-neutralising antibodies
and stimulated with PDGF ligands. After 24 h, the mean
density of cells in the scratched area was calculated and
normalised against the migration induced by growth fac-
tor alone (Figure 6). Cells incubated in serum-free media
containing only mitomycin C migrated the least com-
pared to 10% FBS (p = 0.032 10% FCS vs. Media + mito-
mycin C) (Figure 6b). Similarly, a control IgG did not
appear to have any effect on cell migration when used to
pre-treat cells (p = 0.035 10% FCS vs. IgG treated); how-
ever, when stimulated with PDGF-BB, cells migrated to a
greater extent (50% compared to 10% FCS). When cells
were treated with both the anti-PDGFRα and anti-
PDGFRβ neutralising antibodies or tyrosine kinase in-
hibitor, Imatinib, cell migration was reduced and did not
increase significantly when stimulated with PDGF-BB(p = 0.92 anti-PDGFRα + anti-PDGFRβ vs. anti-
PDGFRα + anti-PDGFRβ + PDGF-BB and p = 0.1
Imatinib vs. Imatinib + PDGF-BB) (Figure 6b). Whilst
both PDGFR neutralising antibodies had an effect in redu-
cing PDGF-induced migration, anti-PDGFRα had the
greatest effect in abrogating PDGF-AA-stimulated migra-
tion compared to the ligand only control (55% migration)
(p = 0.24 anti-PDGFRα + PDGF-AA vs. PDGF-AA, p =
0.93 anti-PDGFRβ + PDGF-AA vs. PDGF-AA) (Figure 6c).
Anti-PDGFRβ was observed to have the greatest effect on
reducing migration stimulated by PDGF-BB (45% com-
pared to 50% when pre-incubated with anti-PDGFRα)
(p = 0.006 anti-PDGFRβ + PDGF-BB vs. PDGF-BB,
p = 0.24 anti-PDGFRα + PDGF-BB vs. PDGF-BB). Simi-
larly, both PDGF-CC (55% compared to 80% when pre-
incubated with anti-PDGFRα) and PDGF-DD-mediated
cell migration were abrogated most effectively by
treatment with anti-PDGFRβ (70% compared to 80%
when pre-incubated with anti-PDGFRα) (p = 0.06 anti-
PDGFRβ + PDGF-CC vs. PDGF-CC, p = 0.34 anti-
PDGFRα + PDGF-CC vs. PDGF-, p = 0.38 anti-PDGFRβ +
PDGF-DD vs. PDGF-DD, p = 0.64 anti-PDGFRα + PDGF-
DD vs. PDGF-DD) (Figures 6d-f). This pattern is also ob-
served in lung fibroblasts (Figure 6g-k). These data show
that treating cells with neutralising antibodies against
PDGFRα and PDGFRβ appears to slow the rate of cell
migration and there is a synergistic inhibitory effect on the
two antibodies.
Discussion
Fibroblasts play a critical role in wound healing and tis-
sue repair [2]. Signalling through the PDGF/PDGFR axis
is a key feature of enhanced migration and ECM synthe-
sis and are required for correct wound healing [1]. How-
ever, dysregulated activity and function of PDGFs are
also believed to be important determinants of human
diseases including excessive dermal scarring, many
forms of organ-based tissue fibrosis as well as vascular
diseases such as atherosclerosis and pulmonary hyper-
tension [27]. It remains to be established whether a par-
ticular combination of PDGF/PDGFR is implicated in
promoting certain disease pathologies.
The phosphorylation pattern of PDGFRα and PDGFRβ
in response to PDGF-ligand stimulation observed in this
study is similar to that previously reported [28-31]. Whilst
it is firmly established that PDGF-AA is most specific for
PDGFRα in vitro, reports vary as to whether phosphoryl-
ation of PDGFRs in response to PDGF-DD stimulation is
PDGFRβ-specific or also stimulates PDGFRα [11,32]. Our
studies indicated that in primary human dermal fibroblasts
PDGF-DD stimulates PDGFRα and PDGFRβ to a similar
extent, consistent with the findings of LaRochelle et al.
[32]. However, a similar pattern of PDGFRα phosphoryl-
ation is not observed in lung fibroblasts. Phosphorylation
Figure 6 The effect on migration of dermal and lung fibroblasts after treatment with PDGFRα and PDGFRβ neutralising antibodies.
Dermal fibroblasts were grown in 10% serum. A scratch was made in the cell layer and cells were treated with mitomycin C with neutralising
antibodies to either anti-PDGFRα, anti-PDGFRβ, anti-PDGFRα and anti-PDGFRβ, control IgG, Imatinib or 10% FCS for 1 h at room temperature and
then stimulated with PDGF-AA, PDGF-BB, PDGF-CC or PDGF-DD. (a). Percentage migration was calculated by measuring the average density of
cells migrated into the scratched area after 24 h (b-f). Error bars are standard errors of the mean. Two-sample T-test was performed - 10% FCS vs.
Media + mitomycin C, 10% FCS vs. IgG treated, anti-PDGFRα + anti-PDGFRβ vs. anti-PDGFRα + anti-PDGFRβ + PDGF-BB, Imatinib vs. Imatinib +
PDGF-BB, p = 0.032, 0.035, 0.92, and 0.1 respectively. Anti-PDGFRα + PDGF-AA vs. PDGF-AA, anti-PDGFRβ + PDGF-AA vs. PDGF-AA, anti-PDGFRβ +
PDGF-BB vs. PDGF-BB, anti-PDGFRα + PDGF-BB vs. PDGF-BB, anti-PDGFRβ + PDGF-CC vs. PDGF-CC, anti-PDGFRα + PDGF-CC vs. PDGF-CC, anti-
PDGFRβ + PDGF-DD vs. PDGF-DD, anti-PDGFRα + PDGF-DD vs. PDGF-DD —p = 0.24, 0.93, 0.006, 0.24, 0.06, 0.34, 0.38 and 0.64 respectively. Lung
fibroblasts were treated and analysed in identical fashion. (g-k). Two-sample T-test was performed - FCS vs. Media + mitomycin C, 10% FCS vs.
IgG treated, anti-PDGFRα + anti-PDGFRβ vs. anti-PDGFRα + anti-PDGFRβ + PDGF-BB, Imatinib vs. Imatinib + PDGF-BB —p = 0.585, 0.18, 0.64 and
0.21 respectively. Anti-PDGFRα + PDGF-AA vs. PDGF-AA, anti-PDGFRβ + PDGF-AA vs. PDGF-AA, anti-PDGFRβ + PDGF-BB vs. PDGF-BB, anti-PDGFRα +
PDGF-BB vs. PDGF-BB, anti-PDGFRβ + PDGF-CC vs. PDGF-CC, anti-PDGFRα + PDGF-CC vs. PDGF-CC, anti-PDGFRβ + PDGF-DD vs. PDGF-DD,
anti-PDGFRα + PDGF-DD vs. PDGF-DD—p = 0.25, 0.75, 0.05, 0.64, 0.82, 0.69, 0.1 and 0.23 respectively.
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cificity as dermal fibroblasts and was shown to be stimu-
lated by all PDGF ligands. This tissue-specific difference in
PDGFR stimulation is a previously unreported finding and
a subject of further investigation.
As deletion of either PDGFR in vivo produces an em-
bryonic lethal phenotype, it is difficult to assess the roles
of the individual PDGF receptors [33-35]. Much of the
previous in vivo work is therefore focused on the contri-
bution of PDGFR in embryonic development. However,some conditional models also exist and work on these
models is becoming increasingly prevalent [36].
Similarly, in vitro it has been difficult to dissect out
receptor-specific signalling pathways as PDGFRs are
reported to have redundancy and display compensatory
effects [20]. Previous work by Wu et al. used specific
PDGFR knockout cell lines created by generating MEFS
from double knockout mice, then transducing retroviral
PDGFRα or PDGFRβ vectors into the cells to express
one or other of the proteins [20]. However, these
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not reflect adult fibroblast function and behaviour. Stud-
ies that examine the effect of specific point mutations of
the PDGFRs in downstream signing pathways have been
useful in dissecting receptor-specific cellular events
[37-39]. However, they offer only limited insights in to
the overall function of the receptor. Conversely, small-
molecular inhibitors such as Gleevec are too broad in
their range of target molecules to define PDGFR-specific
cellular effects [22].
Ingram et al. have used PDGF-AA neutralising anti-
bodies to great effect in the study of cytokine involvement
in lung fibrosis [40]. In this report we investigate the use
of PDGFR-specific neutralising antibodies in dissecting
out PDGFRα- and PDGFRβ-specific events in functional
assays migration and collagen gel remodelling.
We show that neutralising antibodies against PDGFRα
and PDGFRβ block signalling through PDGFRα and
PDGFRβ receptors as expected. The phosphorylation of
each PDGFR receptor was reduced when cells were treated
with specific anti-PDGFRα or anti-PDGFRβ neutralising
antibodies. Similarly we have shown that the neutralising
antibodies abrogate the signal from PDGFRα in specific
downstream signalling cascades. This is best illustrated
in the reduction of pERK in response to anti-PDGFRα
neutralising antibodies in dermal fibroblasts (Figure 4). In
order to determine the efficacy of both the neutralising
antibodies, we previously analysed the phosphorylation of
their PDGFR-α or PDGFR-β receptors using different anti-
bodies raised against a number of different phosphoryl-
ation sites (PDGFR-α Y751 and Y1021, PDGFR-β Y1018
and Y754) (data not shown). In each case we found that
both PDGFR-α and PDGFR-β were not activated and were
henceforth satisfied that the neutralising antibodies had
abrogated normal signal transduction through the recep-
tors. However, stimulation of pERK was observed when
treated with anti-PDGFRβ alone and in the presence of
PDGF-AA and PDGF-BB ligands. Whilst Anti-PDGFRβ
has been previously reported to bind the receptor at a site
other than that of the ligand, and hence not stimulate the
receptor in the conventional manner, it may however
be acting as an auto-antibody. As phosphorylation of
PDGFRβ was not observed in our measurements, it may
be that the signal transduction pathway that mediates the
phosphorylation of ERK may be acting through a different
phosphorylation site on the PDGFRβ receptor. We have
similarly observed a reduction in pAkt in the presence of
anti-PDGFR neutralising antibodies compared to stimula-
tion with PDGF-AA and PDGF-BB ligand in both skin
and lung fibroblasts (data not shown). We do not observe
significant activation of the receptor above the levels of
the ligand alone in lung fibroblasts. The presence of auto-
antibodies that stimulate PDGFRs has previously been
reported by Baroni et al. [41]. We suggest that theneutralisation effect might be limited to actions mediated
by specific phosphorylation sites on the PDGFRβ.
We also show that PDGFR-neutralising antibodies re-
duce PDGF-induced collagen gel remodelling and PDGF-
mediated migration in a manner that reflects known,
well-established receptor/ligand specificities (Figure 1). The
role of PDGF in cell migration has long been established
[4,11]. However, much of the current research has used the
universal PDGF ligand (PDGF-BB) when examining the
role of PDGF signalling in migration. The extent of dermal
fibroblast migration under the various conditions investi-
gated here is in accordance with the known receptor/ligand
specificities. This supports the findings of Gao et al. who
also showed that depletion of PDGFRβ in dermal fibro-
blasts results in decreased migration and therefore validates
the use of neutralising antibodies as a method of dissecting
PDGFR-specific events [36].
The anti-PDGFRα and anti-PDGFRβ antibodies bind at
a different site on the receptors to that of the ligands and
henceforth do not act in a competitive manner. As a con-
sequence of this, it appears as though the neutralising
antibodies do not block signalling through the PDGFRα/
PDGFRβ heterodimer as phosphorylation of the PDGFRα
receptor was still observed when cells were treated with
anti-PDGFRα and stimulated with the universal PDGF lig-
and, PDGF-BB. This is difficult to prove for the PDGFRβ
in the context of this study as there is no PDGFRβ-
specific ligand. This would obviously have to be taken into
consideration in any future studies as a potential caveat.
However, this does enable specific investigation of signal-
ling via PDGFR homodimers only.
Conclusions
Similarly to other deletion strategies, the use of neutral-
isation antibodies has caveats associated with the extent
and length of effect. However, this study has shown that
PDGFRα and PDGFRβ neutralising antibodies can be a




Human dermal and lung fibroblasts were isolated and
cultured as previously described [42]. Cells were maintained
in Dulbecco’s-modified Eagle’s medium (DMEM; Life
Technologies Ltd., UK) supplemented with 10% foetal
bovine serum (Life Technologies), 100 U/ml penicillin and
100 mg/ml streptomycin (Life Technologies) and cultured
in a humidified atmosphere of 5% CO2. At confluence, cells
were passaged 1:4 using trypsin-EDTA (Life Technologies).
Treatment with neutralising antibodies
Cells were cultured in to 90% confluence in DMEM 10%
FBS and serum starved (DMEM 0% FBS) overnight.
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(R&D Systems, UK) were added (10 μg/ml - ND50 1–6
μg/ml based on the manufacturer’s guidelines) to the
cells in fresh serum-free media and incubated for 1 h at
room temperature. Cells were then stimulated with ve-
hicle, PDGF-AA, PDGF-DD, PDGF-CC (R&D Systems) or
PDGF-BB (Abcam UK), at various concentrations (0–200
ng/ml) for either 15 min for Western blot analysis or 24 h
for migration assays.
Western blot analysis
Cell layers were washed in ice-cold PBS and lysed in RIPA
buffer containing protease and phosphate inhibitors (Sigma
UK). Equal amounts of protein (20 μg) were subjected to
SDS/PAGE using 4–12% Bis Tris gels (Life Technologies).
Proteins were blotted onto nitrocellulose as previously
described [43], and proteins were detected using anti-
PDGFRα, anti-PDGFRβ, anti-GAPDH (Abcam, UK), anti-
phospho PDGFRα, anti-phospho PDGFRβ, (R&D Systems),
anti-ERK and anti-phospho ERK antibodies followed by an
appropriate HRP-conjugated secondary antibody (Cell
Signalling, UK). Antibody binding was visualised Proteins
were detected using an enhanced chemiluminescence kit
(Amersham/GE Healthcare, UK).
Migration assay
Cells were plated in 96-well plates and cultured in DMEM
10% FBS to 100% confluency, then serum-starved over-
night. The cell layers were scratched using a 96 pin float-
ing array (V and P Scientific, USA) and washed 2× in PBS.
All media subsequently used were supplemented with mi-
tomycin C (5 ng/ml; Sigma) to block cell proliferation.
Cells were then treated with PDGFR neutralising anti-
bodies as described above, then stimulated with PDGF-
AA, PDGFR-BB, PDGF-CC, PDGF-DD (20 ng/ml) or
vehicle for 24 h and imaged using an Olympus CK2
microscope (Olympus, UK) and Ziess axiocam MR camera
(Carl Zeiss Ltd., UK). Mean density of cells that had
migrated into the scratched area was calculated using
Axio Vision software (Carl Zeiss Ltd.).
Remodelling of collagen matrices
Twenty-four-well plates were coated with 2% bovine
serum albumin (BSA) in PBS (2 ml/well) and incubated
at 37°C overnight. The plates were then washed 3× with
PBS. A collagen gel solution, consisting of one part
0.2 M N-2-hydroxyethylpiperazine-N’-2ethanesulphonic
acid (HEPES), pH 8.0, four parts collagen [3 mg/ml,
First Link (UK) Ltd., UK] and five parts DMEM was
prepared. Cells were treated with neutralising antibodies
against either PDGFRα or PDGFRβ (10 μg/ml) at room
temperature for 1 h. A cell/collagen suspension was
made, with a final concentration of 80,000 cells/ml and
1.2 mg/ml collagen. The cell/collagen suspension (1 mlper well) was added to the plates and incubated at 37°C
to allow the collagen to polymerise. After 1 h, 1 ml of
DMEM containing PDGF-AA, PDGFR-BB (20 ng/ml)
or no serum control was gently added to each well
resulting in detachment of the collagen gels from the
tissue culture plastic. After 24 h, gels were measured
and weighed as a measure of gel contraction [44].
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